Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης Τίτλος Τύπος [ Έτος![(Desc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-desc.png)
Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
Effect of antihypertensive drug-associated diabetes on cardiovascular risk..
Hellenic J Cardiol. 51(3), 195-9.
(2010). Endocrine hypertension: diagnosis and management of a complex clinical entity..
Curr Vasc Pharmacol. 8(5), 646-60.
(2010). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy..
Expert Opin Pharmacother. 11(5), 723-30.
(2010). Lipid-lowering agents and new onset diabetes mellitus..
Expert Opin Pharmacother. 11(12), 1965-70.
(2010). Management of statin-intolerant high-risk patients..
Curr Vasc Pharmacol. 8(5), 632-7.
(2010). Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?.
Curr Pharm Des. 16(34), 3939-847.
(2010). The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification..
Curr Opin Cardiol. 25(4), 394-8.
(2010). Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis..
Lancet. 376(9756), 1916-22.
(2010). Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients..
Neurol Res. 32(3), 326-31.
(2010). Should adipokines be considered in the choice of the treatment of obesity-related health problems?.
Curr Drug Targets. 11(1), 122-35.
(2010). Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?.
Curr Med Res Opin. 26(4), 839-42.
(2010). Statin-fibrate combination for mixed dyslipidaemia: a limited option?.
Curr Med Res Opin. 26(9), 2137-40.
(2010). Statins and heart failure..
J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
(2010). To switch (statins) or not to switch? That is the question..
Expert Opin Pharmacother. 11(18), 2943-6.
(2010). Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?.
Curr Vasc Pharmacol. 8(5), 720-30.
(2010). Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance..
Circ J. 75(8), 2027; author reply 2028.
(2011). Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study..
Curr Med Res Opin. 27(8), 1659-68.
(2011). Atherosclerotic renal artery stenosis: an update on diagnosis and management..
Curr Vasc Pharmacol. 9(4), 465-70.
(2011). Carbon dioxide balneotherapy and cardiovascular disease..
Int J Biometeorol. 55(5), 657-63.
(2011). Current treatment for nonalcoholic fatty liver disease..
Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
(2011). Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment..
Open Cardiovasc Med J. 5, 24-34.
(2011). Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases..
Open Cardiovasc Med J. 5, 85-9.
(2011). Ezetimibe and low density lipoprotein subfractions: an ongoing debate..
Curr Med Res Opin. 27(3), 693-5.
(2011). Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?.
Curr Vasc Pharmacol. 9(6), 698-705.
(2011). Impact of statins on glucose metabolism--a matter of debate..
Am J Cardiol. 107(12), 1866.
(2011).